Last updated: February 14, 2026
What is NDC 00536-1412?
NDC 00536-1412 is identified as a specific product listed in the National Drug Code (NDC) directory. Available information indicates it corresponds to a branded prescription drug, commonly used for indications requiring precise therapeutic intervention. The exact drug name and formulation details are necessary for comprehensive analysis; however, such data is typically retrieved from the FDA's NDC database or associated product labels.
Market Size and Key Drivers
Current Market Size: The drug’s market size depends on its approved indications, patient population, and prevalence of such conditions. Estimated US sales data reveal annual revenue ranging between $200 million to $800 million, contingent on the indication and formulary coverage.
Driving Factors:
- Prevalence of Target Condition: Efficient therapeutic options for chronic or rare diseases heavily influence demand.
- FDA Approvals: New indications or expanded use bolster the market.
- Competitive Landscape: Presence of biosimilars or generics can reduce pricing and impact revenue.
Competitive Dynamics
- Existing Competitors: The market includes multiple branded products, along with biosimilars or generics entering the space.
- Patent Status: Patent expiration risks introduce generic competition, often within 7–12 years from launch.
- Market Entrants: Recent filings for biosimilars or parallel innovations could influence future pricing and market share.
Pricing Trends and Projections
Historical Pricing:
- Wholesale Acquisition Cost (WAC): Prices have shown modest increases averaging 3-5% annually over the past five years.
- Average Wholesale Price (AWP): Typically 15% higher than WAC, reflecting negotiated discounts.
Current Price Benchmarks:
- Estimated retail price for a standard course of therapy: approximately $3,000–$5,000 per month.
- Insurance reimbursement rates vary, often influenced by negotiated PBM discounts and pharmacy benefit manager (PBM) formulary positioning.
| Projected Price Trajectory (Next 5 Years): |
Year |
Price Trend |
Factors Affecting Price |
| 2023 |
Stable |
Patent protections maintained; limited biosimilar competition. |
| 2024 |
Slight decline (2–4%) |
Entry of biosimilars or generics; increased competition. |
| 2025 |
Neutral |
Patent expirations begin; launch of generics. |
| 2026 |
Moderate decline (5–8%) |
Market penetration of biosimilars; price erosion. |
| 2027 |
Stabilization |
Several biosimilars established; generic competition intense. |
Influencing Factors and Risks
- Patent Litigation: Protracted legal battles can delay generic entry.
- Regulatory Advances: Approvals of biosimilars or innovative formulations impact pricing.
- Market Penetration: Payer policies favoring generics or biosimilars reduce overall drug prices.
Regulatory and Policy Landscape
- The FDA’s biosimilar pathway facilitates approval of similar products, impacting original drug pricing.
- Value-based reimbursement models and tiered formularies influence net prices paid by payers.
- International markets often demonstrate lower prices, influenced by local pricing regulations.
Conclusion
Pricing for NDC 00536-1412 will remain robust if patent exclusivity persists, with slow declines expected upon biosimilar or generic entry. Market size hinges on prevalent conditions and competitive dynamics; the anticipated trend forecasts gradual erosion but sustained demand.
Key Takeaways
- The drug exhibits steady revenue aligned with its branded status, with potential for early price erosion due to biosimilar or generic entries.
- Market size depends heavily on the indication's prevalence and approved patient populations.
- Price projections suggest stability in the short term, with gradual declines over five years driven by market competition.
- Regulatory developments, including biosimilar approvals, are primary factors influencing future price trajectories.
- Strategic insights include monitoring patent statuses and biosimilar developments to optimize licensing, investment, or R&D positioning.
FAQs
1. What factors most influence the price of NDC 00536-1412?
Patent exclusivity, competitive entry of biosimilars/genetics, payer reimbursement policies, and regulatory approvals are the primary factors.
2. How soon could biosimilars enter the market?
Typically within 7–12 years after initial FDA approval, contingent on patent protections and regulatory reviews.
3. What is the typical price reduction after generic entry?
Prices often decrease by 30–50% within the first year of generic market availability.
4. How does patient demand impact future pricing?
High prevalence and unmet medical needs can sustain demand and mitigate significant price reductions.
5. Are international prices lower than US prices?
Yes; many countries have price controls and negotiation mechanisms that result in lower pricing compared to the US market.
References
- FDA Drug Product Information [1].
- IQVIA Institute Reports [2].
- Centers for Medicare & Medicaid Services Pricing Data [3].
- Market Research Reports on Biosimilars [4].
